Mersana Therapeutics Investor Relations Material
Mersana Therapeutics Inc., is a biopharmaceutical company focused on discovering and developing a pipeline of antibodies with differentiated and complementary means of targeting cancer. The Company’s lead product candidate is XMT-1522, an ADC that targets the CD38 antigen present on multiple hematological cancers. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics Inc. in November 2005. Mersana Therapeutics Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Key slides for Mersana Therapeutics Inc
From Snap to Roku: Companies That Had Their IPO in 2017
The year 2017 was a significant one for the stock market. It marked the emergence of several game-changing companies that chose to go public. These companies have since influenced various industries and investor portfolios. In this article, we’ll explore the companies that had their IPO in 2017.
21 Jun 2023
🇺🇸 United States